BioCryst Pharma Executive Compensation Revealed
Ticker: BCRX · Form: DEF 14A · Filed: Apr 24, 2025 · CIK: 882796
Sentiment: neutral
Topics: executive-compensation, proxy-statement, equity-awards
Related Tickers: BCRX
TL;DR
BCRX proxy shows exec comp details for 2024 - stock & options.
AI Summary
BioCryst Pharmaceuticals Inc. filed its DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock awards, option awards, and changes in the fair value of outstanding equity awards for its PEO and Non-PEO NEO members. Specific dollar amounts for these awards and their valuations are presented within the compensation tables.
Why It Matters
This filing provides transparency into how BioCryst Pharmaceuticals compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine proxy statement detailing executive compensation and does not present new material risks.
Key Numbers
- 2024 — Fiscal Year (Executive compensation data reported for this year.)
- 2023 — Prior Fiscal Year (Comparative data for executive compensation.)
Key Players & Entities
- BIOCRYST PHARMACEUTICALS INC (company) — Filer
- 0000882796 (company) — Central Index Key
- 20250424 (date) — Filing Date
- 20250612 (date) — Period of Report
- 2024-12-31 (date) — Fiscal Year End
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information regarding the company's annual meeting of shareholders, including details on executive compensation, director nominations, and other corporate governance matters.
Who is the filer of this document?
The filer is BIOCRYST PHARMACEUTICALS INC.
What is the filing date of this document?
The filing date is 20250424.
What fiscal year does the compensation data primarily cover?
The compensation data primarily covers the fiscal year ending December 31, 2024.
What type of compensation elements are detailed in the filing?
The filing details stock awards, option awards, and changes in the fair value of outstanding equity awards for PEO and Non-PEO NEO members.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 24, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).